In the latest edition of Law.com’s Class Actions: Critical Mass briefing, Amanda Bronstad discusses significant developments in high-stakes litigation. Among the notable cases, Johnson & Johnson finds itself back in court, challenged by a preeminent plaintiffs’ expert regarding research that allegedly links its talc products to mesothelioma. This legal contest revives a contentious debate around product safety and scientific evidence.
Meanwhile, new lawsuits have emerged concerning the popular diabetes medication, Ozempic. Allegations have surfaced in approximately a dozen legal actions claiming that the drug may result in blindness in some users. These claims could significantly impact both the pharmaceutical industry and patients relying on the drug.
For further insights and detailed coverage, you can access the full article on Law.com.